See more : Rainbow Children’s Medicare Limited (RAINBOW.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Vir Biotechnology, Inc. (VIR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vir Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bowen Acquisition Corp (BOWNR) Income Statement Analysis – Financial Results
- Jiangxi Jovo Energy Co., Ltd (605090.SS) Income Statement Analysis – Financial Results
- Vonovia SE (VONOY) Income Statement Analysis – Financial Results
- Ragusa Minerals Limited (RAS.AX) Income Statement Analysis – Financial Results
- BitFuFu Inc. (FUFU) Income Statement Analysis – Financial Results
Vir Biotechnology, Inc. (VIR)
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 86.18M | 1.58B | 1.09B | 67.25M | 711.00K | 868.00K | 149.00K |
| Cost of Revenue | 2.77M | 146.32M | 65.87M | 301.58M | 148.47M | 100.23M | 62.51M |
| Gross Profit | 83.42M | 1.43B | 1.02B | -234.33M | -147.76M | -99.36M | -62.36M |
| Gross Profit Ratio | 96.79% | 90.74% | 93.94% | -348.48% | -20,782.14% | -11,447.12% | -41,854.36% |
| Research & Development | 589.67M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 70.94M | 37.60M | 29.13M | 21.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 174.05M | 161.76M | 160.79M | 70.94M | 37.60M | 29.13M | 21.69M |
| Other Expenses | 0.00 | -35.33M | -8.35M | -9.12M | -7.38M | -212.00K | 83.00K |
| Operating Expenses | 767.72M | 601.09M | 600.45M | 364.23M | 178.69M | 119.56M | 81.65M |
| Cost & Expenses | 770.49M | 747.40M | 666.32M | 364.23M | 178.69M | 119.56M | 81.65M |
| Interest Income | 86.99M | 28.09M | 439.00K | 2.84M | 8.51M | 2.54M | 638.00K |
| Interest Expense | 0.00 | 183.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.45M | 15.49M | 11.98M | 8.81M | 4.52M | 2.76M | 432.00K |
| EBITDA | -664.85M | 833.07M | 420.75M | -289.80M | -173.46M | -115.94M | -81.07M |
| EBITDA Ratio | -771.47% | 59.74% | 26.01% | -441.64% | -25,032.21% | -13,356.68% | -54,406.04% |
| Operating Income | -684.31M | 833.07M | 276.89M | -296.98M | -177.98M | -118.69M | -81.50M |
| Operating Income Ratio | -794.04% | 52.71% | 25.47% | -441.64% | -25,032.21% | -13,674.19% | -54,695.97% |
| Total Other Income/Expenses | 56.11M | -78.79M | 129.05M | -1.63M | 3.45M | 2.33M | 721.00K |
| Income Before Tax | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Before Tax Ratio | -728.93% | 47.72% | 50.58% | -444.06% | -24,546.98% | -13,405.99% | -54,212.08% |
| Income Tax Expense | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income Ratio | -713.69% | 32.64% | 48.62% | -444.14% | -24,568.64% | -13,350.69% | -46,880.54% |
| EPS | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -0.72 |
| EPS Diluted | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -0.72 |
| Weighted Avg Shares Out | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 96.91M |
| Weighted Avg Shares Out (Dil) | 134.13M | 134.81M | 133.44M | 119.16M | 107.65M | 96.91M | 96.91M |
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
7 Biotech Stocks to Get In Now Before Investors Catch On
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting® 2023
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Vir Biotech faces steep decline, Bank of America warns amid trial setbacks
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Source: https://incomestatements.info
Category: Stock Reports